KR0179073B1 - 5-ht1 작용물질로서의 인돌 유도체 - Google Patents

5-ht1 작용물질로서의 인돌 유도체 Download PDF

Info

Publication number
KR0179073B1
KR0179073B1 KR1019940703076A KR19940703076A KR0179073B1 KR 0179073 B1 KR0179073 B1 KR 0179073B1 KR 1019940703076 A KR1019940703076 A KR 1019940703076A KR 19940703076 A KR19940703076 A KR 19940703076A KR 0179073 B1 KR0179073 B1 KR 0179073B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
aryl
alkylaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940703076A
Other languages
English (en)
Korean (ko)
Other versions
KR950700291A (ko
Inventor
이. 마코 죤
티. 노와코우스키 졸란타
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR950700291A publication Critical patent/KR950700291A/ko
Application granted granted Critical
Publication of KR0179073B1 publication Critical patent/KR0179073B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019940703076A 1992-03-05 1993-03-03 5-ht1 작용물질로서의 인돌 유도체 Expired - Fee Related KR0179073B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84664092A 1992-03-05 1992-03-05
US846,640 1992-03-05
PCT/US1993/001667 WO1993018032A1 (en) 1992-03-05 1993-03-03 Indole derivatives as 5-ht1 agonists

Publications (2)

Publication Number Publication Date
KR950700291A KR950700291A (ko) 1995-01-16
KR0179073B1 true KR0179073B1 (ko) 1999-03-20

Family

ID=25298499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703076A Expired - Fee Related KR0179073B1 (ko) 1992-03-05 1993-03-03 5-ht1 작용물질로서의 인돌 유도체

Country Status (30)

Country Link
US (2) US5594014A (enExample)
EP (1) EP0629199B1 (enExample)
JP (1) JPH07121943B2 (enExample)
KR (1) KR0179073B1 (enExample)
CN (4) CN1032309C (enExample)
AT (1) ATE218566T1 (enExample)
AU (1) AU666716B2 (enExample)
BR (1) BR9306012A (enExample)
CA (1) CA2117643C (enExample)
CZ (1) CZ282652B6 (enExample)
DE (1) DE69331988T2 (enExample)
DK (1) DK0629199T3 (enExample)
EG (1) EG20416A (enExample)
ES (1) ES2176199T3 (enExample)
FI (1) FI930968A7 (enExample)
HU (1) HU219489B (enExample)
IL (1) IL104941A (enExample)
MX (1) MX9301197A (enExample)
MY (1) MY109298A (enExample)
NO (1) NO302617B1 (enExample)
NZ (1) NZ249755A (enExample)
PL (1) PL172388B1 (enExample)
PT (1) PT629199E (enExample)
RU (1) RU2124012C1 (enExample)
SK (1) SK281938B6 (enExample)
TW (1) TW288010B (enExample)
UA (1) UA39866C2 (enExample)
WO (1) WO1993018032A1 (enExample)
YU (1) YU14893A (enExample)
ZA (1) ZA931539B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
KR0179072B1 (ko) 1992-04-07 1999-03-20 알렌 제이. 스피겔 5-ht1 작동약으로서의 인돌 유도체
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US6288091B1 (en) 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
CZ207298A3 (cs) 1995-12-29 1998-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Fenylthiazolové deriváty, způsob výroby a farmaceutický prostředek
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
SI1339678T1 (sl) 2000-11-27 2007-12-31 Pfizer Prod Inc Selektivni agonisti EP4 receptorja pri zdravljenju osteoporoze
EA200301143A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
ITRM20020255A1 (it) * 2002-05-09 2003-11-10 Polifarma Spa Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.
ES2199086B1 (es) * 2002-07-31 2005-06-01 Cepa Schwarz Pharma Sl Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
IL295374A (en) * 2020-02-04 2022-10-01 Mindset Pharma Inc 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
PL243119B1 (pl) * 2020-04-16 2023-06-26 Univ Jagiellonski Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
DE9190141U1 (de) * 1990-10-15 1993-07-15 Pfizer Inc., New York, N.Y. Indolderivate
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (enExample) * 1991-02-12 1995-11-21 Pfizer

Also Published As

Publication number Publication date
CN1044910C (zh) 1999-09-01
PL172388B1 (pl) 1997-09-30
ZA931539B (en) 1994-09-05
CA2117643A1 (en) 1993-09-16
IL104941A0 (en) 1993-07-08
BR9306012A (pt) 1997-11-18
EG20416A (en) 1999-02-28
RU94040914A (ru) 1996-08-10
SK281938B6 (sk) 2001-09-11
NO302617B1 (no) 1998-03-30
ATE218566T1 (de) 2002-06-15
NO943261D0 (no) 1994-09-02
UA39866C2 (uk) 2001-07-16
CN1136566A (zh) 1996-11-27
ES2176199T3 (es) 2002-12-01
EP0629199A1 (en) 1994-12-21
EP0629199B1 (en) 2002-06-05
YU14893A (sh) 1996-05-20
FI930968A0 (fi) 1993-03-04
PT629199E (pt) 2002-09-30
CN1082815C (zh) 2002-04-17
IL104941A (en) 1998-06-15
CZ282652B6 (cs) 1997-08-13
RU2124012C1 (ru) 1998-12-27
JPH07500353A (ja) 1995-01-12
HU9300593D0 (en) 1993-05-28
JPH07121943B2 (ja) 1995-12-25
CN1032309C (zh) 1996-07-17
DE69331988T2 (de) 2002-09-19
MY109298A (en) 1996-12-31
CN1136432A (zh) 1996-11-27
AU3733093A (en) 1993-10-05
DE69331988D1 (de) 2002-07-11
MX9301197A (es) 1993-09-01
TW288010B (enExample) 1996-10-11
WO1993018032A1 (en) 1993-09-16
US5717102A (en) 1998-02-10
CN1082044A (zh) 1994-02-16
FI930968A7 (fi) 1993-09-06
HU219489B (hu) 2001-04-28
KR950700291A (ko) 1995-01-16
US5594014A (en) 1997-01-14
NZ249755A (en) 1996-08-27
SK105294A3 (en) 1995-05-10
CN1044909C (zh) 1999-09-01
CN1136565A (zh) 1996-11-27
CZ212594A3 (en) 1995-06-14
DK0629199T3 (da) 2002-07-15
CA2117643C (en) 2000-03-14
NO943261L (no) 1994-09-02
AU666716B2 (en) 1996-02-22
HUT64061A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
KR0179073B1 (ko) 5-ht1 작용물질로서의 인돌 유도체
KR0179072B1 (ko) 5-ht1 작동약으로서의 인돌 유도체
KR0163371B1 (ko) 5-아릴인돌 유도체
RU2095360C1 (ru) Производные индола, их оптические изомеры и фармацевтически приемлемые соли
SA05260104A (ar) مشتقات إندول كمساعدات لمستقبل شبه ht1-5
EP2367830A1 (en) 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors
EP0635015B1 (en) Acylaminoindole derivatives as 5-ht1 agonists
CZ290416B6 (cs) Farmaceutický prostředek na bázi derivátu indolu
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
US6380233B1 (en) Indole derivatives as 5-HT1 agonists
IL118910A (en) Intermediates for the synthesis of indole derivatives
JP2005517706A (ja) アデノシンデアミナーゼ阻害活性を有するイミダゾール−４−カルボキサミド
IL121326A (en) N-substituted pyrolidin-2-yl methyl indole derivatives

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E801 Decision on dismissal of amendment
J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-3-3-V10-V13-apl-PJ1201

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20021029

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20031127

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20031127

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000